Epiduo Pediatric Acne Study

NCT ID: NCT01138735

Last Updated: 2021-02-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

285 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-06-30

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and efficacy of Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% administered once daily for up to 12 weeks in subjects 9 to 11 years of age with acne vulgaris.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acne

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

adapalene/benzoyl peroxide

Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% applied topically once daily for 12 weeks

Group Type ACTIVE_COMPARATOR

adapalene/benzoyl peroxide

Intervention Type DRUG

daily topical application for 12 weeks

Topical Gel Vehicle

Topical Gel Vehicle applied topically once daily for 12 weeks

Group Type PLACEBO_COMPARATOR

Topical Gel Vehicle

Intervention Type DRUG

daily topical application for 12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

adapalene/benzoyl peroxide

daily topical application for 12 weeks

Intervention Type DRUG

Topical Gel Vehicle

daily topical application for 12 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Epiduo® (adapalene and benzoyl peroxide) Gel 0.1%/2.5%

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of acne vulgaris with facial involvement
* Score of 3 (moderate) on the Investigator's Global Assessment (IGA) scale
* A minimum of 20 but not more than 100 total lesions (Noninflammatory and/or Inflammatory) on the face (including the nose) at Baseline

Exclusion Criteria

* Acne nodule or acne cyst
* Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), or severe acne requiring systemic treatment
* Underlying diseases and/or dermatologic conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments
* Use of prohibited medications prior to the study and/or are unwilling to refrain from such use during the study
Minimum Eligible Age

9 Years

Maximum Eligible Age

11 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Galderma R&D

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Graeber, MD

Role: STUDY_DIRECTOR

Galderma R&D

Lorne Albrecht, MD

Role: PRINCIPAL_INVESTIGATOR

Guildford Dermatology Specialists

Zoe Draelos, MD

Role: PRINCIPAL_INVESTIGATOR

Zoe Draelos, MD

Lawrence Eichenfield, MD

Role: PRINCIPAL_INVESTIGATOR

Childrens Hospital and Health Center Division of Pediatric and Adolescent Dermatology

Boni Elewski, MD

Role: PRINCIPAL_INVESTIGATOR

UAB Dermatology Clinical Research

Alan Fleischer, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Dermatology Wake Forest University Health Sciences

Francisco Flores, MD

Role: PRINCIPAL_INVESTIGATOR

FXM Research Miramar

Joseph Fowler, MD

Role: PRINCIPAL_INVESTIGATOR

Dermatology Specialists Research

Robert Haber, MD

Role: PRINCIPAL_INVESTIGATOR

Haber Dermatology Clinical Research Center

Adelaide Hebert, MD

Role: PRINCIPAL_INVESTIGATOR

The University of Texas Health Science Center, Houston

Michael Heffernan, MD

Role: PRINCIPAL_INVESTIGATOR

Central Dermatology, PC

David Kaplan, MD

Role: PRINCIPAL_INVESTIGATOR

Adult & Pediatric Dermatology

Steven Kempers, MD

Role: PRINCIPAL_INVESTIGATOR

Minnesota Clinical Study Center A Division of Associated Skin Care Specialist, PA

Rodion Kunynetz, MD

Role: PRINCIPAL_INVESTIGATOR

Ultranova Skincare

Ian Landells, MD

Role: PRINCIPAL_INVESTIGATOR

Nexus Clinical Research

Charles Lynde, MD

Role: PRINCIPAL_INVESTIGATOR

Lynderm Research Inc.

Russell Mader, MD

Role: PRINCIPAL_INVESTIGATOR

Dermatology Associates of Kingsport, PC

Lew Andrew Rosoph, MD

Role: PRINCIPAL_INVESTIGATOR

North Bay Dermatology Centre

Joel Schlessenger, MD

Role: PRINCIPAL_INVESTIGATOR

Skin Specialists, PC

Michael Spigarelli, MD

Role: PRINCIPAL_INVESTIGATOR

Children's Hospital Medical Center, Cincinnati

Linda Stein Gold, MD

Role: PRINCIPAL_INVESTIGATOR

Henry Ford Health Systems - Department of Dermatology

Jeffrey Sugarman, MD

Role: PRINCIPAL_INVESTIGATOR

Redwood Family Dermatology

William Werschler, MD

Role: PRINCIPAL_INVESTIGATOR

Premier Clinical Research

Patricia Westmoreland, MD

Role: PRINCIPAL_INVESTIGATOR

Palmetto Clinical Trial Services, LLC

Andrea Zaenglein, MD

Role: PRINCIPAL_INVESTIGATOR

Penn State Milton S. Hershey Medical Center - Penn State College of Medicine

George Murakawa, MD

Role: PRINCIPAL_INVESTIGATOR

Dermcenter PC; Somerset Skin Centre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UAB Dermatology Clinical Research

Birmingham, Alabama, United States

Site Status

Children's Hospital and Health Center Division of Pediatric and Adolescent Dermatology

San Diego, California, United States

Site Status

Redwood Family Dermatology

Santa Rosa, California, United States

Site Status

FXM Research Miramar

Miramar, Florida, United States

Site Status

Adult & Pediatric Dermatology

Overland Park, Kansas, United States

Site Status

Dermatology Specialists Research

Louisville, Kentucky, United States

Site Status

Henry Ford Health Systems Department of Dermatology

Detroit, Michigan, United States

Site Status

Dermcenter PC - Somerset Skin Centre

Troy, Michigan, United States

Site Status

Minnesota Clinical Study Center A Division of Associated Skin Care Specialists, PA

Fridley, Minnesota, United States

Site Status

Central Dermatology PC

St Louis, Missouri, United States

Site Status

Skin Specialists, PC

Omaha, Nebraska, United States

Site Status

Zoe Draelos, MD

High Point, North Carolina, United States

Site Status

Department of Dermatology - Wake Forest University Health Sciences

Winston-Salem, North Carolina, United States

Site Status

Cininnati Children's Hospital

Cincinnati, Ohio, United States

Site Status

Haber Dermatology Clinical Research Center

South Euclid, Ohio, United States

Site Status

Penn State Milton S. Hershey Medical Center - Penn State College of Medicine

Hershey, Pennsylvania, United States

Site Status

Palmetto Clinical Trial Services, LLC

Greenville, South Carolina, United States

Site Status

Dermatology Associates of Kingsport, PC

Kingsport, Tennessee, United States

Site Status

The University of Texas Health Sciences Center at Houston

Houston, Texas, United States

Site Status

Premier Clinical Research

Spokane, Washington, United States

Site Status

Guildford Dermatology Specialists

Surrey, British Columbia, Canada

Site Status

Nexus Clinical Research

St. John's, Newfoundland and Labrador, Canada

Site Status

Ultranova Skincare

Barrie, Ontario, Canada

Site Status

Lynderm Research, Inc

Markham, Ontario, Canada

Site Status

North Bay Dermatology Centre

North Bay, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RD.06.SPR.18155

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.